Related Experiment Videos
Effect of chronic renal failure on high-density lipoprotein kinetics
1Department of Medicine, Stanford University School of Medicine, California.
Insights
Patients with chronic renal failure (CRF) exhibit higher triglyceride and VLDL-cholesterol levels, alongside lower HDL-cholesterol. This is linked to reduced HDL synthesis and slower removal rates, impacting overall lipoprotein metabolism in CRF.
Area of Science:
- Nephrology
- Cardiovascular Science
- Metabolic Research
Background:
- Chronic renal failure (CRF) is associated with dyslipidemia.
- Understanding lipoprotein metabolism in CRF is crucial for managing cardiovascular risk.
Purpose of the Study:
- To investigate plasma lipid and lipoprotein concentrations.
- To determine high density lipoprotein (HDL) kinetics in patients with CRF compared to controls.
Main Methods:
- Measured plasma lipid and lipoprotein levels.
- Assessed HDL kinetics using 125I-apoAI/HDL clearance rates.
- Compared these parameters between CRF patients and healthy subjects.
Main Results:
- CRF patients showed significantly higher plasma triglyceride and VLDL-cholesterol.
- CRF patients had significantly lower plasma HDL-cholesterol concentrations.
- HDL removal from plasma was slower in CRF patients, increasing residence time and decreasing fractional catabolic rate.
- Lower apoAI concentration in CRF led to a decreased total apoAI/HDL synthetic rate.
Conclusions:
- Low plasma HDL-cholesterol in CRF patients is associated with reduced apoAI/HDL synthetic rates.
- Altered HDL kinetics contribute to dyslipidemia in chronic renal failure.
- These findings highlight the complex relationship between kidney function and lipoprotein metabolism.
Abstract:
Plasma lipid and lipoprotein concentration and high density lipoprotein (HDL) kinetics were determined in control subjects and patients with chronic renal failure (CRF). Results demonstrated that plasma triglyceride (TG) concentration was significantly higher (P less than 0.001) in patients with CRF, associated with a significant increase in plasma VLDL-cholesterol (P less than 0.002) and a significant decrease (P less than 0.05) in plasma HDL-cholesterol concentration. The rate of removal of 125I-apoAI/HDL from plasma was slower (P less than 0.001) in the patients with CRF, resulting in an increase in the residence time of 125I-apoAI/HDL (P less than 0.001) and a decrease in the fractional catabolic rate (P less than 0.001). Since plasma apoAI concentration was lower in patients with CRF, total apoAI/HDL synthetic rate was also significantly (P less than 0.05) decreased. These data provide support for the view that low plasma HDL-cholesterol concentrations in patients with CRF are related to decreases in the synthetic rate of apoAI/HDL.